@article{poizotmartin:hal-01299973,
  TITLE = {{Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study}},
  AUTHOR = {Poizot-Martin, Isabelle and Bellissant, Eric and Garraffo, Rodolphe and Colson, Philippe and Piroth, Lionel and Solas, Caroline and Renault, Alain and Bourli{\`e}re, Marc and Halfon, Philippe and Ghosn, Jade and Alric, Laurent and Naqvi, Alissa and Carrieri, Patrizia and Molina, Jean-Michel},
  URL = {https://univ-rennes.hal.science/hal-01299973},
  JOURNAL = {{HIV Clinical Trials}},
  PUBLISHER = {{Thomas Land Publishers}},
  VOLUME = {17},
  NUMBER = {2},
  PAGES = {63-71},
  YEAR = {2016},
  MONTH = Mar,
  DOI = {10.1080/15284336.2015.1135553},
  KEYWORDS = {direct acting antiviral drug ; boceprevir ; HCV retreatment ; HIV/HCV coinfection},
  PDF = {https://univ-rennes.hal.science/hal-01299973/file/Addition%20of%20boceprevir%20to%20PEG-interferon%20ribavirin_accepted.pdf},
  HAL_ID = {hal-01299973},
  HAL_VERSION = {v1},
}